| Document |
Document Title |
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/094150A1 |
Described herein are NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/095964A1 |
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types ...
|
|
WO/2024/094566A1 |
The present invention relates to compounds of formula (I) as well as to their use as organic doping agent, as transport layer as absorbing layer, as charge injection layer, as organic semiconductor itself, organic semiconductive matrix m...
|
|
WO/2024/097989A1 |
The present disclosure relates to protein degradation inducing compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorde...
|
|
WO/2024/097805A1 |
Disclosed are substituted, heterocycle compounds. The substituted heterocycles disclosed herein are shown to be useful in activating necroptosis by activation of MLKL and may be utilized as therapeutics for treating cancer and cell proli...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/097228A1 |
The present disclosure provides compounds of Formula (I), Formula (II), and Formula (III), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, or prodrugs thereof. The provided compounds may be kinase (e....
|
|
WO/2024/096093A1 |
The present invention provides a compound that has excellent control effects on harmful arthropods. Compounds represented by formula (I) (the meanings of the symbols of which are described in the description) or N-oxides thereof have exc...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/097972A2 |
The present invention describes compounds that inhbits GIT1. The invention further describes compositions containing these GIT1 inhibitors, as well as methods and kits using these GIT1 inhbitors to treat various medical conditions. Medic...
|
|
WO/2024/095177A1 |
The present disclosure provides a manganese bifunctional chelating agent conjugation platform for targeted MR imaging. The platform includes an MRI-active manganese porphyrin (MnP) compound connected to a linker which in turn is connecte...
|
|
WO/2024/095133A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
|
|
WO/2024/093233A1 |
Disclosed herein are alkenyl-terminated tetraarylmetalloporphyrin compounds comprising an ethylene glycol unit, a preparation method therefor, and use thereof. The preparation method for the alkenyl-terminated tetraarylmetalloporphyrin c...
|
|
WO/2024/092420A1 |
A preparation method for a compound VI, the compound VI having a fluorotertiary carbon chiral center and an azaquaternary carbon chiral center, making the compound difficult to synthesize. The preparation method provided by the present a...
|
|
WO/2024/097436A1 |
Compounds for modulating the activity and/or the expression of 5-aminolevulinic acid synthase (ALAS) affecting biological functions. In part, novel compounds and pharmaceutically acceptable salts and in part, methods for preparing the no...
|
|
WO/2024/097559A1 |
The present invention is directed to inhibitors of Kirsten rat sarcoma virus (KRAS) oncoproteins, and more particularly to certain 1,5-napthyridine derivatives of Formula I: as well as compositions comprising Formula I and methods of usi...
|
|
WO/2024/094963A1 |
Provided are 2-amino-pyrido[2,3-d]pyrimidin-7(8H)-one and 7- amino-l-pyrimido[4,5-d]pyrimidin-2(lH)-one derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated for...
|
|
WO/2024/094152A1 |
The present invention relates to a spiro compound, and a preparation method and use thereof. The spiro compound is as shown in formula I, has 3CL protease inhibitory activity, can effectively inhibit RNA virus replication of protein comp...
|
|
WO/2024/097775A1 |
The disclosure relates to anti-cancer compounds derived from nuclear receptor binders, such as nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
|
|
WO/2024/097980A1 |
The present disclosure relates to protein binding compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET that are useful in the treatment of diseases and disorders m...
|
|
WO/2024/088189A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/088311A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.
|
|
WO/2024/089008A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
|
WO/2024/088183A1 |
Provided herein are compounds which exhibit activity in the inhibition of RNA polymerase as well as pharmaceutical compositions comprising these compounds and methods of treatment of viral infections by administration of these compounds ...
|
|
WO/2024/088922A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2024/088069A1 |
Compounds of general formula (I) and formula (II) have good activity for inhibiting tumor growth and have good safety. Provided are preparation for a Kras inhibitor and a use thereof. Specifically, provided are compounds represented by f...
|
|
WO/2024/091498A1 |
Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral c...
|
|
WO/2024/088343A1 |
A novel Kv1.3 channel (or KV1.3) inhibitor, which can be used for preventing and/or treating diseases related to the Kv1.3 channel (or Kv1.3), including immune and inflammatory diseases, such as: multiple sclerosis, inflammatory bowel di...
|
|
WO/2024/088408A1 |
Disclosed are a nitrogen-containing heterocyclic compound, a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Provided is a compound as shown in formula (I) or a pharmaceutically acceptable sal...
|
|
WO/2024/092222A1 |
Methods are provided for modulating MRGPRD generally, or for treating a MRGPRD dependent condition more specifically, by contacting the MRGPRD or administering to a subject in need thereof, respectively, an effective amount of a compound...
|
|
WO/2024/091473A1 |
Disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or diluent and a compound of Formula I: or a pharmaceutically acceptable salt thereof. The variables are defined herein. Also disclosed...
|
|
WO/2024/089191A1 |
A compound of Formula (I) wherein Qa or Qb is N, the other is C, Qc is N or CH, one or two of Q7, Q8, and Q9 are N, the other or the others being CR7, CR8 and CR9 respectively, and the other substituents are as defined in claim 1, useful...
|
|
WO/2024/064701A3 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/088409A1 |
Disclosed in the present invention are nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof, a preparation method therefor, and the use thereof. Provided in the present invention are compounds represen...
|
|
WO/2024/091370A1 |
The present invention provides 5,6-bicyclic heteroaromatic compounds, particularly a compound of formula (I) and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) in treating d...
|
|
WO/2024/088377A1 |
Disclosed are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, X and Y are as defined in the present disclosure.
|
|
WO/2024/046471A9 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/089006A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
|
WO/2024/088184A1 |
Provided herein are compounds which exhibit antiviral activity against feline coronavirus and methods of treatment of feline coronavirus infections by administration of these compounds or the pharmaceutical compositions comprising the same.
|
|
WO/2024/084496A1 |
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmace...
|
|
WO/2024/083024A1 |
Disclosed in the present invention are preparation and a use of a c-RET inhibitor. Specifically, the present invention provides a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical com...
|
|
WO/2024/084217A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
|
|
WO/2024/086296A1 |
The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
|
|
WO/2024/084450A1 |
The present disclosure provides bicyclic heteroaryl compounds and their derivatives of formula (I), which are therapeutically useful as PKMYT1 inhibitors. (I) These compounds are useful in the treatment and/or prevention of diseases or c...
|
|
WO/2024/083773A1 |
The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
|
|
WO/2024/084448A2 |
Compounds of formula (I) and a pharmaceutically acceptable salt thereof, wherein ring A, W, X, Y, L1, R1, R3, and R4, are as defined in the specification, are useful for treating or preventing cancer or an immune-related disease or condi...
|
